RELB Antikörper (pSer573)

Produktnummer ABIN7138653

Der Kaninchen Polyklonal Anti-RELB-Antikörper wurde für WB, ELISA und IHC validiert. Er ist geeignet, RELB in Proben von Human zu detektieren.

Kurzübersicht für RELB Antikörper (pSer573) (ABIN7138653)

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser RELB Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktdetails anti-RELB Antikörper

Bindungsspezifität: pSer573

Kreuzreaktivität: Human, Maus

Aufreinigung: Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi

Immunogen: Peptide sequence around phosphorylation site of serine 573 (L-L-S(p)-P-G) derived from Human RelB.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB:1:500-1:1000, IHC:1:50-1:100,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu RELB

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Andere Bezeichnung: RELB

Hintergrund:

Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.

Marienfeld R, et al. (2001) Oncogene. 20 (56): 8142-7.
Charlotte S. Kaetzel1, et al. (2005) Immunological Reviews Volume 206: 83
Elwira Pyz, et al. (2006) J Immunol. 176:7447-55

Aliases: I REL antibody, I-Rel antibody, IREL antibody, Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody, relB antibody, RELB_HUMAN antibody, Reticuloendotheliosis viral oncogene homolog B antibody, Transcription factor Rel B antibody, Transcription factor RelB antibody, v rel avian reticuloendotheliosis viral oncogene homolog B antibody, v rel reticuloendotheliosis viral oncogene homolog B antibody

UniProt: Q01201

Pathways: NF-kappaB Signalweg, RTK Signalweg